FDA Approves Fixed-Duration Columvi to Treat Relapsed/Refractory DLBCL

Columvi is the first bispecific antibody that can be administered to patients with relapsed or refractory diffuse large B-cell lymphoma for a defined period of time.

Related Keywords

Sweden ,Swedish ,Levi Garraway ,Krish Patel ,Genentech ,Swedish Cancer Institute In Seattle ,Drug Administration ,Swedish Cancer Institute ,Dlbcl ,Diffuse Largeb Cell Lymphoma ,Lymphoma ,